Contract-Resource-Outsourcing-IndustryNews

  1. CryoStim™ Cancer Treatment To Begin FDA Clinical Trials September 1, 2009 8/16/2009
    Immunovative Therapies Ltd. has announced that its CryoStim™ experimental product has been cleared by the FDA to begin human clinical trials. Immunovative Therapies, Ltd. experimental products are based upon “Mirror Effect™” technology (patents issued and pending) which is designed to provide the same anti-tumor effect that has been proven to be curative in allogeneic bone marrow transplant (BMT) procedures without the lethal toxicity or need for a matched donor.
  2. Biota Holdings Announces Successful Phase III Asian Clinical Trials Of Its Second Generation Flu Treatment 8/11/2009
    Biota Holdings Limited (ASX: BTA) today announced successful results from the Asian Phase III clinical trials of CS-8958, its second generation influenza treatment.
  3. Icagen Announces Lifting Of Partial Clinical Hold Of ICA-105665 8/4/2009
    Icagen, Inc. (Nasdaq:ICGN) reported today that the FDA has lifted the partial clinical hold related to the development of ICA-105665, the Company's novel orally available small molecule KCNQ potassium channel agonist, for the treatment of epilepsy.
  4. Avastin Approved In US For The Most Common Type Of Kidney Cancer 8/4/2009
    Avastin is designed to block the vascular endothelial growth factor (VEGF) protein to address a key underlying cause of cancer growth. Avastin works differently than other approved medicines for renal cell carcinoma because it specifically binds to the VEGF protein, which is produced in elevated amounts in most kidney cancers.
  5. European Commission Approves Broader Label For Avastin Allowing Combination With Docetaxel For The First-Line Treatment Of Advanced (Metastatic) Breast Cancer 7/30/2009
    More patients with advanced breast cancer could benefit from Avastin as a result of a broader label allowing Avastin to be combined with both docetaxel or paclitaxel chemotherapy, Roche announced recently. In March 2007, Avastin was approved in Europe for the first-line treatment of patients with advanced breast cancer, in combination with paclitaxel.
  6. Cardiome Achieves Milestone From Collaboration With Merck & Co., Inc. 7/30/2009
    Cardiome Pharma Corp. recently announced that it has earned a US$15M milestone payment from its collaboration with Merck & Co., Inc., through an affiliate. The milestone was triggered by the submission, by Merck, of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) seeking marketing approval for vernakalant (iv) in the European Union.
  7. Generex Publishes Results From Pre-Clinical Studies On Immunotherapeutic Vaccine For HPV-Induced Cervical Cancer 7/23/2009
    Generex Biotechnology Corporation announced today publication of studies demonstrating the anti-cancer activity of a novel Ii-Key/HPV immunotherapeutic vaccine.
  8. Clinical Research Safety And Ethical Standards In Developing World Up To U.S. Levels 7/23/2009
    Clinical trials conducted in the developing world meet the same safety, ethical and quality standards as those conducted in the developed world. That is the conclusion of a major report released recently by the Association of Clinical Research Organizations (ACRO).
  9. Abbott And GSK To Collaborate On Molecular Diagnostic Test To Select Candidate Patients For Future Cancer Immunotherapy 7/14/2009
    Abbott announced recently that it has entered into an agreement with GlaxoSmithKline (GSK) to develop an automated molecular diagnostic test, based on polymerase chain reaction (PCR) technology, intended to screen non-small cell lung cancer (NSCLC) tumors for expression of the MAGE-A3 antigen.
  10. WHO Grants Prequalification To Cervarix: GSK's Vaccine To Help Combat Cervical Cancer In Developing Nations 7/14/2009
    The World Health Organization (WHO) has awarded prequalification to Cervarix, GlaxoSmithKline’s cervical cancer vaccine. The WHO decision is necessary for UN agencies and the GAVI Alliance to purchase the vaccine in partnership with developing countries and will help speed access to Cervarix globally.